Agent Clonality Targets Dosing Halflife Duration of effects Cytokine Release Syndrome? rATG1 Polyclonal Various immune targets, especially T cells Multiple doses (POD2#0-4) 29.8-37.7 days Months to years Yes Basiliximab Monoclonal CD25 (predominantly activated T cells) 2 doses (POD2#0 & 4) 7.2 days Weeks No Daclizumab Monoclonal CD25 (predominantly activated T cells) Multiple doses (POD2#0, then every 2 weeks) 20 days Weeks No Alemtuzumab Monoclonal CD52 (naïve T cells, some B cells, and monocytes) Typically 1 dose (POD2#0) 12 days Months to years Yes (less than rATG1) 1rATG: Rabbit Antithymocyte Globulin; 2POD: Post Operative Day

Table 1: Pharmacological Comparison of Induction Therapy.